Современные подходы к лечению и длительному контролю артериальной гипертонии в клинической практике. Фармакологические и клинические особенности блокаторов рецепторов ангиотензина II: фокус на азилсартана медоксомил. Часть II

1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
2. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
3. Barrios V, Escobar C. Is a new crash coming? J Hypertens Open Access 2012; 1: e105.
4. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (9623): 1513–8.
5. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009; 27 (5): 963–75.
6. Wijeysundera HC, Machado M, Farahati F et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA 2010; 303 (18): 1841–7.
7. Flores-Mateo G, Grau M, O’Flaherty M et al. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988–2005. Rev Esp Cardiol 2011; 64 (11): 988–96.
8. Cifkova R, Skodova Z, Bruthans J et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28 (11): 2196–203.
9. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol 2010; 24 (1): 3–8.
10. Wald DS, Law M, Morris JK et al. Combination Therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 Pacticipants from 42 Trials. Am J Med 2009; 112: 290–300.
11. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–34.
12. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (Suppl. 9): 2–6.
13. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
14. James PA, Oparil S, Carter BL et al. 2014. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. Published online: December 18, 2013. doi:10.1001/jama.2013.284427
15. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control 2014; 7: 35–47.
16. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst 2002; 3 (2): 72–8.
17. McAlister FA, Wilkins K, Joffres M et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011; 183 (9): 1007–13.
18. Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med 2011; 124: 896–9.
19. Kurtz TW. Chlorthalidone: don’t call it “thiazide-like” anymore. Hypertension. 2010; 56: 335–7.
20. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4–9.
21. Materson BJ, Oster JR, Michael UF et al. Dose response to chlorthalidone in patients with mild hypertension, efficacy of a lower dose. Clin Pharmacol Ther 1978; 24: 192–8.
22. Finnerty FA. A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensive's. Angiology 1976; 27: 738–44.
23. Ernst M, Carter B, Goerdt C. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352–8.
24. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104–9.
25. Matthews KA, Brenner MJ, Brenner AC. Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. Clin Ther 2013; 35 (9): 1423–30.
26. Flack J, Sica D, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as a preferred diuretic: is there a verdict yet? Hypertension 2011; 57: 665–6.
27. The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
28. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255–64.
29. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
30. Five-year findings of the hypertension detection and follow-up program. I. reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242 (23): 2562–71.
31. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention trial. Circulation 1990; 82 (5): 1616–28.
32. Dorsch MP, Gillespie BW, Erickson SR еt al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
33. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59: 1110–7.
34. Chen P, Changai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like diuretics: A meta-analysis. Am J Hypertens 2015. doi:10.1093/ajh/hpv050
35. Savage PJ, Pressel SL, Curb JD et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998; 158: 741–51.
36. Ernst ME, Neaton JD, Grimm RH Jr et al. Multiple Risk Factor Intervention Trial Research Group. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension 2011; 58 (6): 1001–7.
37. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 2010; 56 (3): 463–70.
38. Roush GC, Buddharaju V, Ernst ME. Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives? Curr Opin Cardiol 2013; 28 (4): 426–32.
39. McManus RJ, Caulfield M, Williams B; National Institute for Health and Clinical Excellence. NICE Hypertension guideline 2011: evidence-based evolution. BMJ 2012; 344: e181.
40. Nice clinical guideline 127 Hypertension: clinical management of primary hypertension in adults. 2013; www.nice.org.uk/guidance/CG127
41. Sica D, Bakris GL, White WB et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284–92.
42. Shuster JE, Bleske BE, Dorsch MP. Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. Vasc Health Risk Manag 2012; 8: 381–7.
43. Clinical trials.gov. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension. Study NCT00591773. Available from: http://clinicaltrials.gov/ct2/show/ NCT00591773?term =NCT 00591773 &rank=1. Accessed December 13, 2011.
44. Bakris G, Sica D, White WB et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229e1–1229.e10.
45. Pierini D, Anderson KV. Azilsartan Medoxomil/Chlorthalidne: A new Fixed-Dose Combination Antithypertensive. Ann Pharmacother 2013; 47: 694–703.
46. Cushman WC, Sica D, Bakris GL et al. Efficacy and safety of azilsartan medoxomil/chlorthalidone vs olmesartan/HCTZ combinations in Stage 2 systolic hypertension. American Society of Hypertension. Twenty-Sixth Annual Scientific Meeting and Exposition [featured posters, poster 162]. J Clin Hypertens 2011; 13 (S1): A12–A163. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00459.x/abstract
47. Cushman WC, Bakris GL, White WB et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in Stage 2 systolic hypertension. Hypertension 2012; 60: 310–8.
48. Izzo JL Jr, Neutel JM, Silfani T et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007; 9: 36–44.
49. Izzo JL Jr, Weintraub H, Duprez D et al. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich) 2011; 13: 722–30.
50. Neutel JM, Saunders E, Bakris GL et al. on behalf of the INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE Trial. J Clin Hypertens (Greenwich) 2005; 7: 578–86.
51. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801–8.
52. Miura S, Fujino M, Hanzawa H et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006; 281: 19288–95.
53. Sica D, White W, Weber M et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens (Greenwich) 2011; 13: 467–72.
54. White WB, Weber MA, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413–20.
55. Bonner G, Bakris G, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479–86.
56. Potthoff S, Gitt A, Braumgart P et al. Blood pressure reduction by monotherapy with azilsartan as compared to ace inhibitors in clinical practice in GERMANY. Results of the EARLY REGISTRY. J Hypertens 2014; 32: e370–1.
57. Weber MA, White WB, Sica D et al. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension Blood Pressure Monitoring 2014, 19: 90–7.

________________________________________________

1. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159–219.
2. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
3. Barrios V, Escobar C. Is a new crash coming? J Hypertens Open Access 2012; 1: e105.
4. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371 (9623): 1513–8.
5. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009; 27 (5): 963–75.
6. Wijeysundera HC, Machado M, Farahati F et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA 2010; 303 (18): 1841–7.
7. Flores-Mateo G, Grau M, O’Flaherty M et al. Analyzing the coronary heart disease mortality decline in a Mediterranean population: Spain 1988–2005. Rev Esp Cardiol 2011; 64 (11): 988–96.
8. Cifkova R, Skodova Z, Bruthans J et al. Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. J Hypertens 2010; 28 (11): 2196–203.
9. Escobar C, Barrios V. Combined therapy in the treatment of hypertension. Fundam Clin Pharmacol 2010; 24 (1): 3–8.
10. Wald DS, Law M, Morris JK et al. Combination Therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 Pacticipants from 42 Trials. Am J Med 2009; 112: 290–300.
11. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427–34.
12. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs concurrent two-pill therapy in patients with hypertension. Manag Care 2000; 9 (Suppl. 9): 2–6.
13. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens 2014; 32: 3–15.
14. James PA, Oparil S, Carter BL et al. 2014. Evidence-Based Guidelines for the Management of High Blood Pressure in Adulds. Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. Published online: December 18, 2013. doi:10.1001/jama.2013.284427
15. Barrios V, Escobar C. Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control 2014; 7: 35–47.
16. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst 2002; 3 (2): 72–8.
17. McAlister FA, Wilkins K, Joffres M et al. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades. CMAJ 2011; 183 (9): 1007–13.
18. Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med 2011; 124: 896–9.
19. Kurtz TW. Chlorthalidone: don’t call it “thiazide-like” anymore. Hypertension. 2010; 56: 335–7.
20. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4–9.
21. Materson BJ, Oster JR, Michael UF et al. Dose response to chlorthalidone in patients with mild hypertension, efficacy of a lower dose. Clin Pharmacol Ther 1978; 24: 192–8.
22. Finnerty FA. A double-blind study of chlorthalidone and hydrochlorothiazide in an outpatient population of moderate hypertensive's. Angiology 1976; 27: 738–44.
23. Ernst M, Carter B, Goerdt C. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47: 352–8.
24. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59: 1104–9.
25. Matthews KA, Brenner MJ, Brenner AC. Evaluation of the efficacy and safety of a hydrochlorothiazide to chlorthalidone medication change in veterans with hypertension. Clin Ther 2013; 35 (9): 1423–30.
26. Flack J, Sica D, Nesbitt S. Chlorthalidone versus hydrochlorothiazide as a preferred diuretic: is there a verdict yet? Hypertension 2011; 57: 665–6.
27. The ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97.
28. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265: 3255–64.
29. Beckett NS, Peters R, Fletcher AE et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
30. Five-year findings of the hypertension detection and follow-up program. I. reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979; 242 (23): 2562–71.
31. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention trial. Circulation 1990; 82 (5): 1616–28.
32. Dorsch MP, Gillespie BW, Erickson SR еt al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011; 57 (4): 689–94.
33. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59: 1110–7.
34. Chen P, Changai S, Zhao F, Wang DW. Cardioprotective effect of thiazide-like diuretics: A meta-analysis. Am J Hypertens 2015. doi:10.1093/ajh/hpv050
35. Savage PJ, Pressel SL, Curb JD et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998; 158: 741–51.
36. Ernst ME, Neaton JD, Grimm RH Jr et al. Multiple Risk Factor Intervention Trial Research Group. Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension 2011; 58 (6): 1001–7.
37. Woodman R, Brown C, Lockette W. Chlorthalidone decreases platelet aggregation and vascular permeability and promotes angiogenesis. Hypertension 2010; 56 (3): 463–70.
38. Roush GC, Buddharaju V, Ernst ME. Is chlorthalidone better than hydrochlorothiazide in reducing cardiovascular events in hypertensives? Curr Opin Cardiol 2013; 28 (4): 426–32.
39. McManus RJ, Caulfield M, Williams B; National Institute for Health and Clinical Excellence. NICE Hypertension guideline 2011: evidence-based evolution. BMJ 2012; 344: e181.
40. Nice clinical guideline 127 Hypertension: clinical management of primary hypertension in adults. 2013; www.nice.org.uk/guidance/CG127
41. Sica D, Bakris GL, White WB et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284–92.
42. Shuster JE, Bleske BE, Dorsch MP. Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension. Vasc Health Risk Manag 2012; 8: 381–7.
43. Clinical trials.gov. Efficacy and safety of azilsartan medoxomil co-administered with chlorthalidone in participants with essential hypertension. Study NCT00591773. Available from: http://clinicaltrials.gov/ct2/show/ NCT00591773?term =NCT 00591773 &rank=1. Accessed December 13, 2011.
44. Bakris G, Sica D, White WB et al. Antihypertensive efficacy of hydrochlorothiazide vs chlorthalidone combined with azilsartan medoxomil. Am J Med 2012; 125: 1229e1–1229.e10.
45. Pierini D, Anderson KV. Azilsartan Medoxomil/Chlorthalidne: A new Fixed-Dose Combination Antithypertensive. Ann Pharmacother 2013; 47: 694–703.
46. Cushman WC, Sica D, Bakris GL et al. Efficacy and safety of azilsartan medoxomil/chlorthalidone vs olmesartan/HCTZ combinations in Stage 2 systolic hypertension. American Society of Hypertension. Twenty-Sixth Annual Scientific Meeting and Exposition [featured posters, poster 162]. J Clin Hypertens 2011; 13 (S1): A12–A163. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00459.x/abstract
47. Cushman WC, Bakris GL, White WB et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in Stage 2 systolic hypertension. Hypertension 2012; 60: 310–8.
48. Izzo JL Jr, Neutel JM, Silfani T et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007; 9: 36–44.
49. Izzo JL Jr, Weintraub H, Duprez D et al. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich) 2011; 13: 722–30.
50. Neutel JM, Saunders E, Bakris GL et al. on behalf of the INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/HCTZ in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE Trial. J Clin Hypertens (Greenwich) 2005; 7: 578–86.
51. Ojima M, Igata H, Tanaka M et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 2011; 336: 801–8.
52. Miura S, Fujino M, Hanzawa H et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor. J Biol Chem 2006; 281: 19288–95.
53. Sica D, White W, Weber M et al. Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. J Clin Hypertens (Greenwich) 2011; 13: 467–72.
54. White WB, Weber MA, Sica D et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413–20.
55. Bonner G, Bakris G, Sica D et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 2013; 27: 479–86.
56. Potthoff S, Gitt A, Braumgart P et al. Blood pressure reduction by monotherapy with azilsartan as compared to ace inhibitors in clinical practice in GERMANY. Results of the EARLY REGISTRY. J Hypertens 2014; 32: e370–1.
57. Weber MA, White WB, Sica D et al. Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension Blood Pressure Monitoring 2014, 19: 90–7.

М.Г.Бубнова

ФГБУ Государственный научно-исследовательский центр профилактической медицины Минздрава России. 101990, Россия, Москва, Петроверигский пер., д. 10, стр. 3
mbubnova@gnicpm.ru

________________________________________________

M.G.Bubnova

State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation. 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3
mbubnova@gnicpm.ru